Testing Newborn Meconium Reveals Cannabis Exposure That Mothers Don't Report

Meconium testing detected prenatal cannabis and alcohol exposure that maternal self-reports missed, though sample sizes for positive cannabis results were small.

Lamy, Sandrine et al.·Journal of psychiatric research·2017·Moderate EvidenceCross-Sectional
RTHC-01425Cross SectionalModerate Evidence2017RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Cross-Sectional
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

This study compared what mothers reported about their substance use during pregnancy with what objective testing of their newborns' meconium (first stool) actually revealed.

For tobacco, meconium cotinine testing agreed well with maternal self-reports (Kappa = 0.79), and meconium testing actually predicted neonatal consequences of tobacco exposure better than self-reports alone.

For cannabis and alcohol, the story was different. Agreement between self-reports and meconium testing was low for both alcohol (Kappa = 0.13) and cannabis (Kappa = 0.30). Notably, the highest levels of alcohol metabolites in meconium were found in babies whose mothers denied drinking, suggesting significant underreporting of prenatal alcohol exposure.

Among 645 meconium samples collected from 724 mothers across all maternity units in Rouen, France, over two 5-week periods, polyconsumption (using multiple substances) was actually less common than expected based on meconium testing. An interesting finding in dizygotic twins showed that fetal exposure to substances can differ substantially even between twins sharing the same pregnancy.

Key Numbers

724 mothers, 645 meconium samples. Tobacco agreement: Kappa = 0.79. Alcohol agreement: Kappa = 0.13. Cannabis agreement: Kappa = 0.30. Total cannabinoid-positive meconium samples were small in number.

How They Did This

Cross-sectional study of 724 mothers and 645 meconium samples collected within 72 hours of delivery across all maternities in Rouen, Normandy. Maternal self-reports used the Addiction Severity Index (5th edition). Meconium was tested for cotinine (tobacco), ethyl-glucuronide (alcohol), and cannabinoid metabolites.

Why This Research Matters

Prenatal substance exposure has significant effects on neonatal health and child development. If mothers underreport cannabis and alcohol use during pregnancy, clinicians relying solely on self-reports will miss exposures. Meconium testing provides an objective alternative that captures third-trimester exposure.

The Bigger Picture

The discrepancy between self-reported and objectively measured prenatal substance exposure has implications for both clinical care and research. Studies relying on maternal self-reports may systematically underestimate prenatal cannabis and alcohol exposure rates, leading to underestimation of associated health effects.

What This Study Doesn't Tell Us

The number of cannabis-positive and alcohol-positive meconium samples was small, limiting statistical precision for these substances. Meconium reflects only third-trimester exposure and may miss earlier pregnancy use. Cultural factors in France may affect reporting patterns differently than in other countries.

Questions This Raises

  • ?Should routine meconium screening be implemented in clinical practice?
  • ?Would non-judgmental screening environments improve maternal self-reporting accuracy?
  • ?How does first-trimester cannabis exposure (missed by meconium) compare in neonatal effects to third-trimester exposure?

Trust & Context

Key Stat:
Maternal self-reports and meconium testing agreed poorly for cannabis (Kappa = 0.30) and alcohol (Kappa = 0.13)
Evidence Grade:
Well-designed cross-sectional study with objective biomarker validation across all maternities in a defined region. Moderate because cannabis-positive sample sizes were small.
Study Age:
Published in 2017, with data from August 2010 and August 2011.
Original Title:
Assessment of tobacco, alcohol and cannabinoid metabolites in 645 meconium samples of newborns compared to maternal self-reports.
Published In:
Journal of psychiatric research, 90, 86-93 (2017)
Database ID:
RTHC-01425

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

A snapshot of a population at one point in time.

What do these levels mean? →

Frequently Asked Questions

Do mothers accurately report cannabis use during pregnancy?

This study found poor agreement between maternal self-reports and objective meconium testing for cannabis (Kappa = 0.30), suggesting significant underreporting. Self-reports were more reliable for tobacco use.

What is meconium testing?

Meconium is a newborn's first stool, which accumulates during pregnancy and contains metabolites of substances the fetus was exposed to during the third trimester. Testing it provides an objective measure of prenatal exposure independent of what the mother reports.

Read More on RethinkTHC

Cite This Study

RTHC-01425·https://rethinkthc.com/research/RTHC-01425

APA

Lamy, Sandrine; Hennart, Benjamin; Houivet, Estelle; Dulaurent, Sylvain; Delavenne, Heloise; Benichou, Jacques; Allorge, Delphine; Marret, Stéphane; Thibaut, Florence. (2017). Assessment of tobacco, alcohol and cannabinoid metabolites in 645 meconium samples of newborns compared to maternal self-reports.. Journal of psychiatric research, 90, 86-93. https://doi.org/10.1016/j.jpsychires.2017.02.012

MLA

Lamy, Sandrine, et al. "Assessment of tobacco, alcohol and cannabinoid metabolites in 645 meconium samples of newborns compared to maternal self-reports.." Journal of psychiatric research, 2017. https://doi.org/10.1016/j.jpsychires.2017.02.012

RethinkTHC

RethinkTHC Research Database. "Assessment of tobacco, alcohol and cannabinoid metabolites i..." RTHC-01425. Retrieved from https://rethinkthc.com/research/lamy-2017-assessment-of-tobacco-alcohol

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.